$CLOV

Wai Conrad sold $1.4M of CLOV (indirect holdings)

Wai Conrad (CEO, Counterpart Health) sold 300,000 indirectly-held shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.72 ($1.42M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wai Conrad
Published Sep 16, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Bearish
medium confidence
Mentioned
$CLOV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVBearishLow
01

Why it matters

The disclosed sale reduces the CEO's ownership but follows a pre‑arranged plan, limiting immediate market impact.

02

Market read

Primary relevance is to CLOV shareholders; broader market effect is limited.

03

What to watch

The 10b5-1 plan pre‑arranged nature may mitigate negative interpretation.

Relevance 5/10Novelty 4/10Timing: filed after market close on 2026-09-16

Background

Clover Health Investments filed a Form 4 reporting an insider transaction by its CEO.

Company-level read

Ticker impact

$CLOVBearishMedium confidence
Context

CEO Wai Conrad sold 300,000 shares for $1.416M via a 10b5-1 plan, reducing his stake to 1,170,056 shares.

Expected impact

possible modest downside of 1-2% in the near term

Evidence & confidence

Large insider sale of $1.4M, but executed under a pre‑arranged plan, limits immediate market reaction.

Market effects

Minimal impact on health‑tech sector; similar insider sales have limited sector ripple.

U.S. market only; no broader regional effect.

Low global relevance.

Counterpoint

The sale could be routine liquidity management, not a bearish signal.

Key entities

  • Wai Conrad

    CEO of Clover Health Investments, Counterpart Health

  • Clover Health Investments, Corp.

    U.S.-listed health‑tech firm (ticker CLOV)

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLOVHigh

Why is Clover Health stock climbing 4% today?

Clover Health (CLOV) stock rose 4.3% in pre-market trading after Needham initiated coverage with a Buy rating and $6.00 price target, citing its Medicare Advantage rating and cohort economics. The company's upcoming conference presentation and Q3 earnings report also contributed to the positive sentiment. The Nasdaq Composite was up 0.5% in pre-market.

$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.

$CLOVHigh

Why Is Clover Health (CLOV) Stock Soaring Today

Clover Health (CLOV) stock rose 10.7% premarket after CMS awarded its PPO Medicare Advantage plans a 5-Star rating and HMO plans a 4.5-Star rating for 2027. The ratings, excluding disputed measures, boost payments and enrollment. Shares later cooled to $4.81, up 5%. CLOV is up 99.5% YTD but still below its 52-week high.

$CLOVMed

Is Clover Health Stock Too Dependent On One Group Of Members?

Clover Health Investments (CLOV) reported that nearly half of its Medicare Advantage members joined in 2025 or 2026, impacting short-term profits. Membership grew 48% YoY to 157,000, with new members accounting for 49%. Despite a 70% stock return over 12 months, CLOV's revenue declined 0.7%, and gross profit grew slower than revenue. Management raised full-year guidance but cautioned about future trends.

$CLOVMed

Clover Health Medicare Advantage PPO Plans Earn 5-Star Rating; HMO at 4.5 Stars

Clover Health's PPO Medicare Advantage plans received a 5.0 Star rating and HMO plans 4.5 Stars for 2027, impacting 2028 payments. CMS removed 20 measures for PPO plans, raising their rating. Clover's MA membership grew ~48% YoY to >157,000 members, with 98% in PPO plans. The company ranked #1 among non-SNP PPO plans with >2,000 members on core HEDIS measures, scoring 4.82 out of 5.